Cancer research boosters

Spending on cancer research in Britain has increased by half, a conference is to be told today.

The National Cancer Research Institute brings together the major organisations that back cancer research – and it is meeting for its annual conference in Birmingham today.

In five years, from 2002, some £1.6 billion was spent on cancer research in Britain, the conference was due to hear.

By 2006 annual spending reached some £393 million, some £135 million more than in 2002.

The NCRI said spending on cancer prevention research had doubled – but cancers of the lung, pancreas and oesophagus remain hard to treat and research.

Director Dr Jane Cope said: "These figures show the extent to which investment in research is mirrored by increasing survival rates – which is great news. But it’s of concern that we’re not seeing the same improvements for some of the harder to treat cancers.

"There is a ‘snowball effect’ at work here – the more a cancer is researched, the more avenues are opened for further work. Well understood cancers like breast and leukaemia have a critical mass of research behind them that has been built over many years and which leads to more research and promising findings."

* Meanwhile a £50 million boost for cancer imaging was also announced in a joint project between Cancer Research UK and the Engineering and Physical Sciences Research Council.

Four major imaging centres are to be set up – three in London and one in Oxford. Oxford University will also get some £2 million for a new cyclotron.

And five further research programmes will be set up in Birmingham, Surrey, St Andrew’s, Newcastle and Sheffield with annual grants of up to £500,000. In Birmingham the cash will go to the Childhood Cancer and Leukaemia Group.

* Researchers will report success in treating testicular cancer today. A Medical Research Council study has found that the anti-cancer drug carboplatin can treat a form of the cancer knwn as seminoma, replacing radiotherapy.

Some 573 patients treated with the drug all survived the cancer and experienced fewer side effects than radiotherapy patients.

Researcher Dr Ben Mead, of Southampton University, said: "The initial results of the trial looked encouraging, but we needed to follow patients for another four years before we knew for sure that they had been cured.

"These follow up results are very reassuring and have already changed practice in Europe. We hope that carboplatin injections will become the standard treatment for this disease across the rest of the world within a few years."

,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index